GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch.
"We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview.
The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year.
GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month.
On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.
Persons:
Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle
Organizations:
GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson
Locations:
British, U.S, Europe, Japan, United States